Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 558.04$. Average daily volumn in 3 months 757.9k. Market cap 61.90B



Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 581.01$. Total volume : 474.81k. Market state PRE
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price
581.01$
Change
3.23
Volume
474.81k

Previous Close577.78
Open568.51
Day Range566.16-581.19
Bid0.00 x 1.1k
Ask0.00 x 1.4k
Volume474.81k
Average Volume757.9k
Market Cap61.9B
Beta0.18
52 Week Range441.00-660.00
Trailing P/E16.54
Foward P/E14.50
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2020 were 8.31B an increase( +33.33%) over the years 2019 revenue that were of 6.56B. In 2020 the company's total earnings were 3.51B while total earnings in 2019 were 2.12B( +50%).


Loading ...



Organization

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch r... etinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc._logo

Market Cap:
61.90B
Revenue:
8.31B
Total Assets:
17.16B
Total Cash:
2.19B


News about "Regeneron Pharmaceuticals, Inc."

Regeneron In R&D Deal With AstraZeneca For Treatment Of Obesity_image

Regeneron In R&D Deal With AstraZeneca For Treatment Of Obesity

Regeneron Pharmaceuticals, Inc. (REGN) and AstraZeneca (AZN) on Tuesday said they are teaming up to research, develop and commercialize small molecule medicines to treat obesity and related ...

Source from : Nasdaq - 1 days ago


Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca today announced that the companies have entered into a collaboration to research, develop and commercialize small molecule compounds ...

Source from : YAHOO!Finance - 1 days ago


Humana sues Regeneron over pricing of popular macular degeneration drug_image

Humana sues Regeneron over pricing of popular macular degeneration drug

The lawsuit is based on claims by the Justice Department that Regeneron paid charity kickbacks to boost sales of the drug ...

Source from : Modern Healthcare - 1 days ago


Regeneron, AstraZeneca to develop obesity treatment

Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Tuesday after the company announced a deal with AstraZeneca ...

Source from : Business Insider - 1 days ago


Regeneron Pharmaceuticals Sued Due to Alleged Pricing Scheme

Humana Inc. filed suit against Regeneron Pharmaceuticals, Inc. Thursday in the Southern District of New York over allegations that the pharmaceutical ...

Source from : Law Street Media - 4 days ago


Will Regeneron Stock See Higher Levels After A 9% Rise In A Month?_image

Will Regeneron Stock See Higher Levels After A 9% Rise In A Month?

However, now that REGN stock has seen a rise of 9% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance ...

Source from : Nasdaq - 5 days ago


Duke, Regeneron, Micronoma Named 2021 Bio-IT World Innovative Practices Winners

Bio-IT World has announced the 2021 Innovative Practices Awards winners. Grand prize awards were granted to Duke Cancer Institute with University of California, San Francisco, Micronoma, and Regeneron ...

Source from : Bio IT World - 12 hours ago


Regeneron 'Kickbacks' Fueled Blockbuster Profits, Suit Says

Insurance company Humana Inc. has accused Regeneron of inflating the cost of its vision loss drug Eylea by operating a purported scheme to make charitable donations to offset the price that patients ...

Source from : Law360 - 4 days ago


Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay's Ministry of Public ...

Source from : Le Lézard - 12 days ago


AstraZeneca partners with Regeneron to research obesity treatment

Anglo-Swedish pharmaceutical firm AstraZeneca PLC on Tuesday announced a collaboration agreement with New York-based biotechnology firm Regeneron Pharmaceuticals Inc to research and develop small ...

Source from : London South East - 1 days ago


Regeneron plans $1.8 billion expansion of Westchester County campus_image

Regeneron plans $1.8 billion expansion of Westchester County campus

The drug developer's investment, announced Thursday, is expected to create 1,000 new full-time, high-skill jobs.

Source from : The Business Journals - 12 days ago


Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy?

However, in this article we will take a look at their collective moves over the last 6 years and analyze what the smart money thinks of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) based on that data.

Source from : Yahoo News - 1 month ago


Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers_image

Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target ...

Source from : Benzinga.com on MSN.com - 6 days ago


Japan Approves Regeneron's Antibody Cocktail To Treat Mild To Moderate COVID-19

Japan's Ministry of Health, Labour and Welfare has approved Regeneron Pharmaceuticals Inc.'s (REGN) casirivimab and imdevimab ...

Source from : Business Insider - 8 days ago


BRIEF-Japan Becomes First Country To Approve Regeneron Antibody Cocktail For The Treatment Of Mild To Moderate Covid-19

JAPAN BECOMES FIRST COUNTRY TO APPROVE REGENERON ANTIBODY COCKTAIL (CASIRIVIMAB AND IMDEVIMAB) FOR THE TREATMENT OF MILD TO MODERATE COVID-19 * REGENERON-JAPAN'S MINISTRY OF HEALTH APPROVED CO'S ...

Source from : Reuters on MSN.com - 8 days ago


Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Regeneron Pharmaceuticals (REGN) been one of those stocks this year? Let's take ...

Source from : YAHOO!News - 7 days ago


Pharma Ophthalmic Market Report Covers Future Trends With Research 2021-2027 | Regeneron, Pfizer, Roche, Allergan, Akorn_image

Pharma Ophthalmic Market Report Covers Future Trends With Research 2021-2027 | Regeneron, Pfizer, Roche, Allergan, Akorn

The updated report on the Pharma Ophthalmic market gives a precise analysis of the value chain assessment for the review period of 2021 to 2027. The research includes an exhaustive evaluation of the ...

Source from : manometcurrent.com - 2 days ago


Chugai Pharmaceutical Obtains Approval for Covid Antibody Cocktail

Chugai Pharmaceutical Co. obtained regulatory approval in Japan for a Covid-19 antibody cocktail created by Regeneron Pharmaceuticals Inc. The Japanese unit of Swiss drug maker Roche Holding AG said ...

Source from : Morningstar, Inc. - 8 days ago


Zacks.com featured highlights include: Dollar General, Canon, Tyler Technologies, Regeneron Pharmaceuticals and Fanhua_image

Zacks.com featured highlights include: Dollar General, Canon, Tyler Technologies, Regeneron Pharmaceuticals and Fanhua

Stocks in this week’s article are Dollar General Corporation DG, Canon Inc. CAJ, Tyler Technologies, Inc. TYL, Regeneron Pharmaceuticals, Inc. REGN and Fanhua Inc. FANH. Many investors are quite ...

Source from : YAHOO!Finance - 6 days ago


Global Retinal Disorder Treatment Market Technology Prospectus to 2027 – Genentech Inc., REGENERON, Pfizer Inc., Graybug Vision, Inc._image

Global Retinal Disorder Treatment Market Technology Prospectus to 2027 – Genentech Inc., REGENERON, Pfizer Inc., Graybug Vision, Inc.

Request Sample is Available @ The global Retinal Disorder Treatment Market is anticipated to reach the market size of xx million USD in 2026 from xx million USD in 2020 by registering a CAGR value of ...

Source from : manometcurrent.com - 8 days ago


Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy?

However, in this article we will take a look at their collective moves over the last 6 years and analyze what the smart money thinks of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) based on that data.

Source from : Insider Monkey - 1 month ago


Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center ® (RGC) have discovered rare genetic mutations in the GPR75 gene associated ...

Source from : PR Newswire - 27 days ago


Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated

Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael ...

Source from : Benzinga.com - 28 days ago


Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity

In a July 2 research note, H.C. Wainwright & Co. analyst Michael King reported that "investment in Regeneron Pharmaceuticals Inc. (REGN:NASDAQ) pays off again" with its identification of a novel ...

Source from : streetwisereports.com - 18 days ago


Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center® (RGC) have discovered rare genetic mutations in the GPR75 gene associated with ...

Source from : Morningstar%2c Inc. - 26 days ago


Regeneron Pharmaceuticals (REGN) Presents At Guggenheim's Biopharma Next Decade: Views from the Top on Global Strategy and Innovation - Slideshow

Thanks, SA Transcripts Team The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with this event.

Source from : Seeking Alpha - 25 days ago


Large-Scale Genetic Study Identifies Variants That Protect Against Obesity

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center® (RGC) have discovered rare genetic mutations in the GPR75 gene associated with ...

Source from : technologynetworks.com - 20 days ago


Regeneron Genetics Center discovers gene mutations that protect against obesity

DANVILLE, Pa. –Scientists from the Regeneron Genetics Center (RGC) have discovered rare genetic mutations in the GPR75 gene that are associated with protection against obesity. As part of the research ...

Source from : KLAS Press Release - 22 days ago


Intellia Shoots High on New Deal with Regeneron

Jun 28, 2021 (Baystreet.ca via COMTEX) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose sharply in Monday trading. Intellia Therapeutics and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

Source from : MarketWatch - 29 days ago


2 Biotech Stocks That are Dirt Cheap Right Now

Considering the industry’s solid growth prospects, we believe shares of biotechnology companies Gilead Sciences, Inc. (GILD) and Regeneron Pharmaceuticals, Inc. (REGN) are attractively cheap at ...

Source from : Entrepreneur - 15 days ago


Silverback Therapeutics in Supply Agreement for Libtayo With Regeneron

Silverback Therapeutics Inc. said it is in a clinical supply agreement with Regeneron Pharmaceuticals Inc. for Libtayo cemiplimab. Silverback said the supply agreement supports the evaluation of ...

Source from : MarketWatch - 20 days ago


Regeneron Pharmaceuticals Inc.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Source from : Wall Street Journal - 15 days ago


Crispr Gene-Editing Breakthrough Is a Big Deal. How Big?

For the first time, the gene-modifying technology was shown to work in the human body to treat disease, offering huge hope for further uses. Here’s what you need to know. Sam Fazeli, a Bloomberg ...

Source from : Bloomberg - 29 days ago


Long-Term Data Reinforces Dupilumab Safety Profile in Adults with Moderate-to-Severe Atopic Dermatitis

The European Medicines Agency will update the dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc) summary of product characteristics with long-term safety results for adults with moderate-to-severe ...

Source from : Pharmacy Times - 27 days ago


Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial

Clinical-stage genome editing company Intellia Therapeutics Inc. (NTLA:NASDAQ) and biotechnology firm Regeneron Pharmaceuticals Inc. (REGN:NASDAQ), announced "positive interim data from an ongoing ...

Source from : streetwisereports.com - 1 month ago


Tuesday's Top Analyst Upgrades and Downgrades: Carvana, CSX, FedEx, Fox, Marathon, Petro China, Planet Fitness, Regeneron and More

The consensus price target is $26.50. Regeneron Pharmaceuticals Inc. (NASDAQ: REGN): H.C. Wainwright initiated coverage with a Buy rating and a $703 price target. The shares last closed near $543 ...

Source from : 24/7 Wall St - 29 days ago


Cathie Wood Funds Jump As Gene Editing Edges Closer To Reality

Ark is also the second largest holder in Beam Therapeutics Inc., another company working on fixing genetic mutations. All four stocks rallied after Intellia and Regeneron Pharmaceuticals Inc ...

Source from : Financial Advisor - 1 month ago


Cathie Wood Funds Jump as Gene Editing Edges Closer to Reality

Ark is also the second largest holder in Beam Therapeutics Inc., another company working on fixing genetic mutations. All four stocks rallied after Intellia and Regeneron Pharmaceuticals Inc. produced ...

Source from : Yahoo Finance - 29 days ago


Japanese pharma seeks approval for 'antibody cocktail' drug combination to treat COVID-19

This electron microscope photo provided by the National Institute of Infectious Diseases shows the coronavirus isolated at the facility. (Photo Courtesy of the National Institute of Infectious ...

Source from : mainichi.jp - 27 days ago


Sanofi to Sell Regeneron Shares Worth $11.1 Billion to Fund Overhaul

Sanofi SA is to offload most of its long-held stake in Regeneron Pharmaceuticals Inc., giving the company an $11.1 billion war chest to help reshape its drug pipeline as it doubles down on rare ...

Source from : ADVFN - 26 days ago


'A new era of medicine': In a first for CRISPR, Intellia edits cells inside the body

The Cambridge biotech, working with Regeneron Pharmaceuticals (Nasdaq ... including Editas Medicine Inc. (Nasdaq: EDIT) — which was also co-founded by Doudna — and diagnostics startup Sherlock ...

Source from : The Business Journals - 29 days ago


IVERIC bio, Inc. Announces Proposed Offering of Common Stock

IVERIC bio, Inc. (the "Company"), today announced that it is commencing an underwritten public offering of shares of its common stock. In addition, the Company intends to grant the underwriters an ...

Source from : Le Lézard - 15 days ago


Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Latest Stock Performance A Reflection Of Its Financial Health?

Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 11% over the last three months. Since the market usually pay for a company’s ...

Source from : Yahoo Finance - 1 month ago


Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail

Regeneron Pharmaceuticals, Inc. REGN announced positive results from the RECOVERY trial in the U.K. on antibody cocktail, REGEN-COV (casirivimab and imdevimab), for COVID-19. The phase III trial ...

Source from : MSN - 1 month ago


Regeneron drug reduces COVID-19 patient deaths in large study

Regeneron Pharmaceuticals Inc.’s antibody cocktail reduced the risk of death by 20% among hospitalized COVID-19 patients who don’t have a natural antibody response of their own, according to a ...

Source from : The Japan Times - 1 month ago